[1]
|
卢青, 陶雪飞, 程标, 等. 他汀类药物对高龄动脉粥样硬化性心血管疾病患者衰弱程度的影响研究[J]. 中华老年医学杂志, 2019, 38(3): 309-311.
|
[2]
|
魏妤. 动脉粥样硬化性心血管疾病的降胆固醇治疗及进展[J]. 中国临床医生杂志, 2019, 47(4): 379-381.
|
[3]
|
Mahmood, S.S., Levy, D., Vasan, R.S., et al. (2014) The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective. The Lancet, 383, 999-1008.
https://doi.org/10.1016/S0140-6736(13)61752-3
|
[4]
|
孟晓萍, 胡大一. 坚持他汀中国剂量主旋律[J]. 医学与哲学, 2017, 38(18): 9-11.
|
[5]
|
Cholesterol Treatment Trialists C, Fulcher, J., O’Connell, R., et al. (2015) Efficacy and Safety of LDL-Lowering Therapy among Men and Women: Meta-Analysis of Individual Data from 174,000 Participants in 27 Randomised Trials. The Lancet, 385, 1397-1405. https://doi.org/10.1016/S0140-6736(14)61368-4
|
[6]
|
Feng, S.J., Tang, Z.H., Wang, Y., et al. (2019) Potential Protective Effects of Red Yeast Rice in Endothelial Function against Atherosclerotic Cardiovascular Disease. Chinese Journal of Natural Medicines, 17, 50-58.
https://doi.org/10.1016/S1875-5364(19)30009-3
|
[7]
|
Liu, L., Zhao, S.P., Cheng, Y.C., et al. (2003) Xuezhikang Decreases Serum Lipoprotein(a) and C-Reactive Protein Concentrations in Patients with Coronary Heart Disease. Clinical Chemistry, 49, 1347-1352.
https://doi.org/10.1373/49.8.1347
|
[8]
|
Zheng, J., Xiao, T., Ye, P., et al. (2017) Xuezhikang Reduced Arterial Stiffness in Patients with Essential Hypertension: A Preliminary Study. Brazilian Journal of Medical and Biological Research, 50, e6363.
https://doi.org/10.1590/1414-431x20176363
|
[9]
|
Liu, Z.Q., Cui, L.Q. and Wang, Y. (2007) Effect of Xuezhikang on Cardiac Function, Serum C-Reactive Protein and Blood Lipid in Patients with Chronic Heart Failure. Chinese Journal of Integrated Traditional and Western Medicine, 27, 220-222.
|
[10]
|
Hong, X.Z., Li, L.D. and Wu, L.M. (2007) Effects of Fenofibrate and Xuezhikang on High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease. Clinical and Experimental Pharmacology and Physiology, 34, 27-35.
https://doi.org/10.1111/j.1440-1681.2007.04547.x
|
[11]
|
Li, M., He, Q., Chen, Y., et al. (2015) Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trails. Evidence-Based Complementary and Alternative Medicine, 2015, Article ID: 468520. https://doi.org/10.1155/2015/468520
|
[12]
|
Li, J.J., Lu, Z.L., Kou, W.R., et al. (2009) Beneficial Impact of Xuezhikang on Cardiovascular Events and Mortality in Elderly Hypertensive Patients with Previous Myocardial Infarction from the China Coronary Secondary Prevention Study (CCSPS). The Journal of Clinical Pharmacology, 49, 947-956. https://doi.org/10.1177/0091270009337509
|
[13]
|
诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版) [J]. 中华全科医师杂志, 2017, 16(1): 15-35.
|
[14]
|
郭远林, 陈纪林. 从美国2018胆固醇管理指南看非他汀类降脂药物新证据[J]. 中国循环杂志, 2019, 34(3): 221-223.
|
[15]
|
Jiang, D., Wang, Y., Chang, G., et al. (2019) DNA Hydroxymethylation Combined with Carotid Plaques as a Novel Biomarker for Coronary Atherosclerosis. Aging (Albany NY), 11, 3170-3181. https://doi.org/10.18632/aging.101972
|
[16]
|
Zhao, F.F., Gao, H.Y., Gao, Y., et al. (2018) A Correlational Study on Cerebral Microbleeds and Carotid Atherosclerosis in Patients with Ischemic Stroke. Journal of Stroke & Cerebrovascular Diseases, 27, 2228-2234.
https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.04.009
|
[17]
|
Banach, M., Patti, A.M., Giglio, R.V., et al. (2018) The Role of Nutraceuticals in Statin Intolerant Patients. Journal of the American College of Cardiology, 72, 96-118. https://doi.org/10.1016/j.jacc.2018.04.040
|
[18]
|
Banach, M., Stulc, T., Dent, R., et al. (2016) Statin Non-Adherence and Residual Cardiovascular Risk: There Is Need for Substantial Improvement. International Journal of Cardiology, 225, 184-196.
https://doi.org/10.1016/j.ijcard.2016.09.075
|
[19]
|
Rosenson, R.S., Baker, S., Banach, M., et al. (2017) Optimizing Cholesterol Treatment in Patients with Muscle Complaints. Journal of the American College of Cardiology, 70, 1290-1301. https://doi.org/10.1016/j.jacc.2017.07.752
|
[20]
|
Reiner, Z. (2010) Combined Therapy in the Treatment of Dyslipidemia. Fundamental & Clinical Pharmacology, 24, 19-28. https://doi.org/10.1111/j.1472-8206.2009.00764.x
|
[21]
|
Mazza, A., Schiavon, L., Rigatelli, G., et al. (2018) The Short-Term Supplementation of Monacolin K Improves the Lipid and Metabolic Patterns of Hypertensive and Hypercholesterolemic Subjects at Low Cardiovascular Risk. Food & Function, 9, 3845-3852. https://doi.org/10.1039/C8FO00415C
|
[22]
|
Kasliwal, R.R., Bansal, M., Gupta, R., et al. (2016) ESSENS Dyslipidemia: A Placebo-Controlled, Randomized Study of a Nutritional Supplement Containing Red Yeast Rice in Subjects with Newly Diagnosed Dyslipidemia. Nutrition, 32, 767-776. https://doi.org/10.1016/j.nut.2016.01.012
|
[23]
|
Wang, T.J., Lien, A.S., Chen, J.L., et al. (2019) A Randomized Clinical Efficacy Trial of Red Yeast Rice (Monascus pilosus) against Hyperlipidemia. The American Journal of Chinese Medicine, 47, 323-335.
https://doi.org/10.1142/S0192415X19500150
|
[24]
|
Cao, R., Bai, Y., Sun, L., et al. (2014) Xuezhikang Therapy Increases miR-33 Expression in Patients with Low HDL-C Levels. Disease Markers, 2014, Article ID: 781780. https://doi.org/10.1155/2014/781780
|
[25]
|
Räber, L., Taniwaki, M., Zaugg, S., et al. (2015) Effect of High-Intensity Stain Therapy on Atherosclerosis in Non-Infarct-Related Cornary Areries (IBIS-4): A Serial Intravascular Ultrasonography Study. European Heart Journal, 36, 490-500. https://doi.org/10.1093/eurheartj/ehu373
|
[26]
|
Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., et al. (2004) Effect of Intensive Compared with Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: A Randomized Controlled Trial. JAMA, 291, 1071-1080.
https://doi.org/10.1001/jama.291.9.1071
|
[27]
|
Nissen, S.E., Nicholls, S.J., Sipahi, I., et al. (2006) Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA, 295, 1556-1565. https://doi.org/10.1001/jama.295.13.jpc60002
|
[28]
|
Nicholls, S.J., Ballantyne, C.M., Barter, P.J., et al. (2011) Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine, 365, 2078-2087. https://doi.org/10.1056/NEJMoa1110874
|
[29]
|
Lee, C.W., Kang, S.J., Ahn, J.M., et al. (2012) Comparison of Effects of Atorvastatin (20 mg) versus Rosuvastatin (10 mg) Therapy on Mild Coronary Atherosclerotic Plaques (from the ARTMAP Trial). The American Journal of Cardiology, 109, 1700-1704. https://doi.org/10.1016/j.amjcard.2012.01.399
|
[30]
|
Takayama, T., Hiro, T., Yamagishi, M., et al. (2009) Effect of Rosuvastatin on Coronary Atheroma in Stable Coronary Artery Disease: Multicenter Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS). Circulation Journal, 73, 2110-2117.
https://doi.org/10.1253/circj.CJ-09-0358
|
[31]
|
冯建国, 王玉琴. 小剂量瑞舒伐他汀联合血脂康对肾动脉粥样硬化性高血压的疗效及安全性分析[J]. 健康前沿, 2019, 28(4): 205.
|
[32]
|
郑思道, 杨翠, 张成英. 血脂康胶囊治疗血脂异常的Meta分析[J]. 中国医药导报, 2019, 16(14): 51-55+78.
|